Orega Biotech
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Orega Biotech - overview
Established
2010
Location
Ecully, -, France
Primary Industry
Biotechnology
About
Orega Biotech, based in France, focuses on developing innovative immunotherapeutic products aimed at treating cancer through monoclonal antibodies. Founded in 2010 and headquartered in Ecully, France, Orega Biotech specializes in immunotherapy for cancer. The company has undergone significant strategic focus on monoclonal antibody development since its inception. In June 2014, Turenne Capital invested in Orega Biotech, marking a pivotal moment in its funding history.
Orega Biotech specializes in the development of innovative immunotherapeutic products aimed at treating cancer through novel monoclonal antibodies. Their flagship product is a humanized CD39 antibody, which is currently undergoing Phase 2 clinical trials for its efficacy in non-small cell lung cancer (NSCLC). This product targets immune checkpoints and regulators of antitumoral immunity, with the intention of enhancing the effectiveness of existing cancer therapies and improving patient survival rates. Orega Biotech collaborates with leading pharmaceutical companies such as Innate Pharma and AstraZeneca to advance the clinical development of its antibody programs.
The primary markets for these products include Europe, North America, and potentially other regions with established healthcare infrastructures focused on oncology. Orega Biotech generates revenue primarily through collaboration agreements and licensing arrangements with pharmaceutical partners. Their business model is structured around partnerships with major industry players, facilitating the advancement of their therapeutic products from development to commercialization. For example, the CD39 antibody program is partnered with AstraZeneca, which involves milestone payments and royalties based on sales performance upon successful commercialization.
The transactions are structured on B2B agreements, wherein Orega Biotech collaborates closely with its partners to leverage their distribution channels and market access for the products. Additional revenue can also be derived from research grants and funding associated with their clinical trials and development projects. Orega Biotech plans to further develop its CD39 antibody and expand into additional markets, including Asia and South America, by 2025. The recent investment from Turenne Capital in June 2014 is expected to support product development and entry into these new geographic regions.
The company is also exploring new immunotherapeutic products to complement its existing portfolio, aiming for additional clinical trials in the coming years.
Current Investors
OCTALFA, Sham - Société Hospitalière d’Assurances Mutuelles
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy
Website
www.orega-biotech.com/
Total Amount Raised
Subscriber access only
Orega Biotech - financials
| Fiscal Year Ended | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 293,250 | - | 776,667 | 7,303,333 | 3,098,867 | 1,578,941 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | 840.3% | (57.6%) | (49.0%) | - | - | - |
| EBITDA (USD) | 1,150,903 | - | 123,671 | 5,161,050 | 1,557,991 | 479,763 | - | - | - |
| Operating Income (USD) | 1,150,903 | - | 113,453 | 5,150,611 | 1,548,256 | 477,731 | - | - | - |
| Operating Margin | 392.5% | - | 14.6% | 70.5% | 50.0% | 30.3% | - | - | - |
| % EBITDA Margin | 392.5% | - | 15.9% | 70.7% | 50.3% | 30.4% | - | - | - |
| NET Income (USD) | 1,293,191 | - | 302,270 | 4,848,810 | 1,806,270 | 955,365 | - | - | - |
| % Net Margin | 441.0% | - | 38.9% | 66.4% | 58.3% | 60.5% | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.